nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
Government Barriers to Condom Use by Men Who Have Sex With Men
Volume 2 · Supplement 4 · November 2016
ISSN 2055-66-40 – Print
Foreword
| ISSN 2055-66-59 – Online
www.viruseradication.com
PNAS 2022 Vol. 119 No. 7 e2109217118
March – June 2020
This update: 3 April 2020
This report is produced by the UNDAC Team in Lima. It is developed in collaboration with the partners of the National Humanitarian Network (RHN). It covers the period from 27 to 30 March 2017. The next report will be issued around April 3, 2017
Towards Attaining the Highest Standard of Mental Health